Brain Health
Four Neurology Drug Approvals Reshaping Brain Disease Treatment
From Alzheimer's to Parkinson's, a wave of novel FDA approvals is expanding treatment options for serious neurological conditions.
Drug Approval
May 8, 2026 0
Results for "Inflammaging Therapeutics"
20 articles
Cancer Research
FDA Approves Oral AML Therapy for Elderly Patients Unfit for Intensive Chemo
Inqovi gains approval for newly diagnosed AML in patients 75+ or with comorbidities, offering a gentler oral treatment route.
Drug Approval
May 22, 2026 0
Metabolic Health
Orforglipron Oral GLP-1 Pill Approved as Obesity Pipeline Heats Up
The FDA reportedly approved Eli Lilly's orforglipron, a daily oral GLP-1 receptor agonist for obesity, marking a potential shift from injectable weight-loss drugs.
Drug Approval
Apr 21, 2026 0
Brain Health
FDA Approves Four Neurological Drugs Targeting Alzheimer's, Glioma, and Rare Disease
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
Drug Approval
May 5, 2026 0
Metabolic Health
FDA Approves Baxfendy, a New Aldosterone Synthase Inhibitor for Hypertension
Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.
Drug Approval
May 19, 2026 0
Cancer Research
Nivolumab Gets FDA Nod for Classical Hodgkin Lymphoma in 2025 Drug Approval Wave
MSK-led research drove 10 FDA cancer drug approvals in 2025, including nivolumab combined with chemotherapy for classical Hodgkin lymphoma.
Drug Approval
May 26, 2026 0
Cancer Research
MSK Research Drives 11 FDA Cancer Drug Approvals in 2025
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
Drug Approval
May 19, 2026 0
Heart Health
FDA Approves Aficamten for Obstructive Hypertrophic Cardiomyopathy
Myqorzo (aficamten) wins FDA approval for symptomatic obstructive HCM, offering a novel cardiac myosin inhibitor option for patients.
Drug Approval
Jun 14, 2026 0
Brain Health
FDA Approves First Drug to Treat Neurologic Complications of Hunter Syndrome
Avlayah (tividenofusp alfa-eknm) becomes the first therapy approved to address brain damage in Hunter syndrome, a rare pediatric disorder.
Drug Approval
Apr 28, 2026 0
Cancer Research
FDA Approves Two New HER2-Targeted Lung Cancer Drugs in 2025
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
Drug Approval
May 24, 2026 0
Cancer Research
FDA Greenlights Two New HER2-Targeted Lung Cancer Drugs in Recent Months
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
Drug Approval
Apr 28, 2026 0
Cancer Research
FDA Approves Sonrotoclax for Hard-to-Treat Mantle Cell Lymphoma
Sonrotoclax (Beqalzi), a next-gen BCL-2 inhibitor, wins accelerated FDA approval for relapsed or refractory MCL after BTK inhibitor failure.
Drug Approval
May 15, 2026 0
Cancer Research
FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Drug Approval
May 6, 2026 0
Brain Health
FDA Approves First Drug for Hunter Syndrome Brain Complications in Children
Avlayah becomes the first treatment targeting neurologic symptoms of rare genetic disorder affecting 500 Americans.
Drug Approval
Apr 15, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Non-Small Cell Lung Cancer
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
Drug Approval
May 1, 2026 0
Metabolic Health
FDA Approves First Oral GLP-1 Weight Loss Pill Orforglipron
Foundayo (orforglipron) becomes the first oral GLP-1 receptor agonist approved for obesity, offering a pill alternative to injectable Wegovy.
Drug Approval
May 9, 2026 0
Cancer Research
FDA Approves Nivolumab Combination Regimen for Classical Hodgkin Lymphoma
Nivolumab plus standard chemotherapy receives FDA approval for classical Hodgkin lymphoma, expanding immunotherapy's role in blood cancers.
Drug Approval
May 27, 2026 0
Cancer Research
FDA Approves Nivolumab Combo for Classical Hodgkin Lymphoma
Nivolumab added to standard chemotherapy wins FDA approval, offering a new frontline option for classical Hodgkin lymphoma patients.
Drug Approval
May 26, 2026 0
Cancer Research
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
Drug Approval
Apr 21, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
Drug Approval
Apr 20, 2026 0
Page 1 of 2Next